Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Overview of attention for article published in Blood, December 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

policy: 2 policy sources
patent: 1 patent

reddit: 1 Redditor
guideline: 6 clinical guideline sources

Readers on

mendeley: 171 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 04 May 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Adcetris for Hodgkin’s Lymphoma (post-ASCT) Resubmission – Details - Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 10 Aug 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.